{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:56:27Z","timestamp":1793134587573,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2172,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Basic Science Research Program"},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science, and Technology","doi-asserted-by":"crossref","award":["NRF-2010-0011577"],"award-info":[{"award-number":["NRF-2010-0011577"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1093\/annonc\/mdt379","type":"journal-article","created":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T02:59:02Z","timestamp":1379645942000},"page":"3089-3094","source":"Crossref","is-referenced-by-count":126,"title":["A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes"],"prefix":"10.1016","volume":"24","author":[{"given":"S.M.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.K.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.Y.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.H.","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.W.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.G.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.I.","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.Y.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.U.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.C.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt379_bb0010","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0140-6736(03)12488-9","article-title":"Thyroid carcinoma","volume":"361","author":"Sherman","year":"2003","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt379_bb0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clon.2010.03.014","article-title":"Cytotoxic chemotherapy for differentiated thyroid carcinoma","volume":"22","author":"Sherman","year":"2010","journal-title":"Clin Oncol"},{"key":"10.1093\/annonc\/mdt379_bb0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2265.2004.02037.x","article-title":"Medullary thyroid carcinoma","volume":"61","author":"Leboullex","year":"2004","journal-title":"Clin Endocrinol"},{"key":"10.1093\/annonc\/mdt379_bb0025","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3349\/ymj.2012.53.2.352","article-title":"Treatment outcome of patients with anaplastic thyroid cancer: a single center experience","volume":"53","author":"Lim","year":"2012","journal-title":"Yonsei Med J"},{"key":"10.1093\/annonc\/mdt379_bb0030","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt379_bb0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Mosetanib diphosphate in progressive differentiated thyroid cancer","volume":"359","author":"Sherman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt379_bb0040","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"28","author":"Gupta-Abramson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt379_bb0045","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Phase 2 study of sunitinib in refractory thyroid cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt379_bb0050","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt379_bb0055","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1158\/1078-0432.CCR-11-2700","article-title":"Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases","volume":"18","author":"Tamburrino","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt379_bb0060","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/14728222.2011.594044","article-title":"The mTOR protein as a target in thyroid cancer","volume":"15","author":"Souza","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1093\/annonc\/mdt379_bb0065","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1158\/0008-5472.CAN-09-1077","article-title":"Genetic alterations in the phosphoinositide 3-kinase\/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdt379_bb0070","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.surg.2011.09.022","article-title":"Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas","volume":"150","author":"Kouvaraki","year":"2011","journal-title":"Surgery"},{"key":"10.1093\/annonc\/mdt379_bb0075","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/j.1582-4934.2011.01438.x","article-title":"Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study","volume":"16","author":"Faggiano","year":"2012","journal-title":"J Cell Mol Med"},{"key":"10.1093\/annonc\/mdt379_bb0080","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1210\/jc.2009-0662","article-title":"Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer","volume":"10","author":"Jin","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mdt379_bb0085","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1093\/annonc\/mdt379_bb0090","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt379_bb0095","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1158\/1078-0432.CCR-10-0802","article-title":"Phase II study of everolimus in previously treated small cell lung cancer","volume":"16","author":"Tarhini","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt379_bb0100","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial","volume":"9","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt379_bb0105","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419367286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419367286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/12\/3089\/16702083\/mdt379.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:30:59Z","timestamp":1624505459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419367286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0923753419367286"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt379","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718113892.793485442","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}